Skip to Primary Navigation

Skip to main content

New UK competition rules to affect global deal reviews for tech and pharma

The logo of the French pharmacy and vaccine company, Sanofi is displayed during the Viva Technology show at Parc des Expositions Porte de Versailles.
Photo: Chesnot/Getty Images

Joshua M. Goodman | Morgan Lewis, Omar Shah | Morgan Lewis, Leonidas Theodosiou | Morgan Lewis+1

8 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

The pharma industry has been the focus of recent competition investigations in the UK, EU and US.

The UK Digital Markets, Competition and Consumers Act 2024 (UK DMCC), which received Royal Assent in May 2024, makes several significant changes to the UK Competition and Markets Authority (UK CMA) and the country’s competition laws relevant to merger review. Among those changes, the UK DMCC introduced a new threshold

The

, , , , , , , , ,

Get full access, free for a month

Start your 28-day free trial to continue reading and access
all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience